Loading...
•
Mar 31, 2022
BioCryst Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
Key Takeaways
BioCryst Pharmaceuticals reported total revenues of $49.9 million for the first quarter of 2022, primarily driven by $49.7 million in ORLADEYO net revenue. The company is investigating BCX9930 and plans to discuss a revised dosing protocol with regulators by the end of the third quarter.
ORLADEYO net revenue reached $49.7 million in Q1 2022.
Full year 2022 ORLADEYO net revenue is expected to be no less than $250 million.
The company is investigating the BCX9930 clinical program due to observed elevations in serum creatinine.
The company plans to discuss a revised dosing protocol for BCX9930 with regulators by the end of the third quarter.
Forward Guidance
BioCryst anticipates full year 2022 net ORLADEYO revenue to be no less than $250 million. The company will provide an updated outlook on full year 2022 operating expenses after completing its investigation into BCX9930.
Positive Outlook
- Full year 2022 net ORLADEYO revenue is expected to be no less than $250 million.
Challenges Ahead
- The company is investigating the BCX9930 clinical program due to observed elevations in serum creatinine.
- The U.S. Food and Drug Administration (FDA) informed the company that it has placed the clinical program for BCX9930 on a partial clinical hold.
- The company may not enroll new patients in its BCX9930 clinical trials.
- Operating expenses outlook is pending the completion of the BCX9930 investigation.
- The company does not plan to provide additional updates on the BCX9930 program until it completes additional regulatory discussions and has more clarity on the next steps for the program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...